Trial ID: | L5300 |
Source ID: | NCT01461499
|
Associated Drug: |
Aliskiren
|
Title: |
Shiga Microalbuminuria Reduction Trial-2
|
Acronym: |
|
Status: |
COMPLETED
|
Study Results: |
YES
|
Results: |
https://ClinicalTrials.gov/show/NCT01461499/results
|
Conditions: |
Type 2 Diabetes Mellitus|Hypertension
|
Interventions: |
DRUG: Aliskiren|DRUG: any angiotensin receptor blockers
|
Outcome Measures: |
Primary: Reduction in Albuminuria, Change in the urinary albumin to creatinine ratio (UACR) from the baseline, baseline and 24 weeks | Secondary: Change in the Urinary Angiotensinogen Level, Change in the urinaryurinary angiotensinogen level from the baseline, baseline and 24 weeks|Change in the Plasma Renin Activity, baseline and 24 weeks|Change in the Serum Insulin Level, baseline and 24 weeks
|
Sponsor/Collaborators: |
Sponsor: Shiga University
|
Gender: |
ALL
|
Age: |
ADULT, OLDER_ADULT
|
Phases: |
PHASE4
|
Enrollment: |
237
|
Study Type: |
INTERVENTIONAL
|
Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
Start Date: |
2011-10
|
Completion Date: |
2014-12
|
Results First Posted: |
2018-02-19
|
Last Update Posted: |
2018-02-19
|
Locations: |
Shiga University of Medical Science, Otsu, Shiga, 520-2192, Japan
|
URL: |
https://clinicaltrials.gov/show/NCT01461499
|